Hep C drug also active against zika

May 19, 2016 News BioVox

Scientists from KU Leuven have shown that the experimental antiviral drug 7DMA against hepatitis C slows down the development of the Zika virus in mice. The study, carried out by the Laboratory of Virology and Chemotherapy and led by Prof. Johan Neyts also disposes of a panel of experimental assays to identify inhibitors of the zika virus and an animal model to study zika- infection.
So far no vaccine or antiviral therapies are available for the prevention or treatment of zika infections, which can result in neurological and auto-immune complications in infants and adults.


Reference

Zmurko et al. The Viral Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLOS neglected tropical diseases (2016)

 


Avatar photo
BioVox

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter